GlaxoSmithKline Pharmaceuticals Ltd. announced that Juby Chandy will step down as Whole-Time Director & CFO, transitioning to a new APAC finance leadership role. The Board has appointed Ronojit Biswas as Whole-Time Director & CFO for a three-year term starting April 1, 2026.
GlaxoSmithKline Pharmaceuticals Ltd. has confirmed a significant leadership change at the finance helm. Juby Chandy, Whole-Time Director & CFO, will step down effective March 11, 2026, after a distinguished tenure. She will move into a new APAC finance leadership role within the GSK Group.
Key Highlights
-
Resignation & Transition: Juby Chandy exits her CFO role, continuing her career within GSK’s Asia-Pacific operations.
-
New Appointment: The Board has approved Ronojit Biswas as Whole-Time Director & CFO for a three-year term beginning April 1, 2026.
-
Experience: Biswas brings over 25 years of GSK experience, most recently serving as Senior Finance Director – Global Product Strategy in Singapore.
-
Strategic Context: The transition ensures continuity in financial leadership while strengthening GSK’s global finance strategy.
-
Market Reaction: Shares of GSK Pharma traded steady post-announcement, reflecting investor confidence in the succession plan.
Why It Matters
Leadership changes at the CFO level are pivotal for governance and investor sentiment. GSK’s seamless succession plan highlights its commitment to financial stability and global integration.
Sources: ScanX News, Reuters, GSK Exchange Filing